Trajan Wealth LLC Invests $8.31 Million in Stryker Corporation $SYK

Trajan Wealth LLC acquired a new stake in shares of Stryker Corporation (NYSE:SYK) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 26,392 shares of the medical technology company’s stock, valued at approximately $8,309,000.

Several other institutional investors and hedge funds have also bought and sold shares of SYK. Brighton Jones LLC boosted its stake in shares of Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after acquiring an additional 609 shares during the last quarter. Schnieders Capital Management LLC. purchased a new stake in shares of Stryker in the 2nd quarter worth $205,000. Marshall Wace LLP raised its holdings in Stryker by 107.9% in the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock worth $2,255,000 after purchasing an additional 77,831 shares during the period. Nebula Research & Development LLC purchased a new position in Stryker during the second quarter valued at $219,000. Finally, HUB Investment Partners LLC purchased a new position in Stryker during the second quarter valued at $253,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Stock Performance

NYSE SYK opened at $327.80 on Tuesday. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $396.86. The business has a 50-day moving average price of $327.39 and a 200-day moving average price of $332.16. The firm has a market cap of $125.73 billion, a price-to-earnings ratio of 33.97, a price-to-earnings-growth ratio of 2.10 and a beta of 0.76.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same quarter last year, the company earned $3.13 EPS. The firm’s quarterly revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities research analysts predict that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Analyst Upgrades and Downgrades

SYK has been the subject of a number of analyst reports. Wolfe Research cut Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday, August 13th. JPMorgan Chase & Co. lowered their price objective on Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. Evercore set a $350.00 price objective on Stryker in a research note on Monday, July 6th. Deutsche Bank Aktiengesellschaft set a $315.00 target price on shares of Stryker in a report on Friday, May 1st. Finally, Citigroup restated a “buy” rating on shares of Stryker in a research note on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $386.28.

Insider Transactions at Stryker

In other Stryker news, insider Debra King sold 826 shares of Stryker stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the sale, the insider directly owned 6,210 shares in the company, valued at approximately $2,088,423. The trade was a 11.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Ronda E. Stryker sold 300,000 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the completion of the sale, the director owned 2,301,375 shares in the company, valued at approximately $773,031,862.50. The trade was a 11.53% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 355,370 shares of company stock valued at $119,447,201. 4.60% of the stock is currently owned by corporate insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.